Congenital adrenal hyperplasia market seen reaching $0.7 billion by 2030

Nov. 20, 2026
Congenital adrenal hyperplasia market seen reaching $0.7 billion by 2030
By AI, Created 14:30 UTC, Nov 20, 2026, AGP -

The congenital adrenal hyperplasia market is projected to grow from $0.5 billion in 2025 to $0.7 billion by 2030, driven by gene therapy interest, broader genetic testing and new steroid formulations. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Congenital adrenal hyperplasia is a lifelong inherited disorder, so changes in treatment access and technology can affect long-term patient care, diagnosis and disease management. - The market outlook points to steady growth as more patients may benefit from improved screening, precision medicine and newer drug formats.

What happened: - The Business Research Company said the congenital adrenal hyperplasia market is projected to rise from $0.5 billion in 2025 to $0.53 billion in 2026. - The report forecasts the market will reach $0.7 billion by 2030. - The report puts the market at a 7.1% CAGR from 2025 to 2026 and a 6.8% CAGR through 2030. - The company released a 2026 report on the market that covers trends, size and forecasts for 2026-2035. - North America held the largest share of the market in 2025. - Asia-Pacific is forecast to post the fastest growth in the coming years.

The details: - CAH is a group of inherited disorders caused by enzyme deficiencies that impair adrenal gland function, most commonly 21-hydroxylase deficiency. - Treatment centers on hormone replacement therapy to restore cortisol and aldosterone, suppress excess androgen production and address electrolyte imbalances and abnormal physical development. - Historical market growth has been shaped by limited enzyme replacement therapies, reliance on lifelong glucocorticoid treatments, low awareness in developing countries, delayed diagnosis from inadequate screening and dependence on hospital-based endocrinology services. - Growth is expected to be supported by advances in precision medicine, wider access to genetic testing, higher healthcare spending, more specialty clinics and better patient compliance from new drug formulations. - Anticipated trends include broader newborn screening programs, long-acting and modified-release steroid therapies, improved mineralocorticoid and androgen suppression protocols, wider use of multidisciplinary care models and more lifetime disease management. - Gene therapy is a key growth catalyst because CAH is caused by mutations that affect adrenal hormone production. - The American Society of Gene and Cell Therapy reported in April 2024 that 1,023 gene therapies were in development for rare diseases. - The same ASGCT update said 76 gene therapy trials launched in the second quarter of 2024, up 25% from the previous quarter. - The report says those gene therapy trends support the outlook for CAH treatment research and market growth. - The report covers North America, Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, key technologies and future trends, plus updated graphics and tables. - The report offers a free sample and a full version through the company's website: free sample and full market report.

Between the lines: - The growth story is less about a single breakthrough and more about several changes building together, including better screening, more specialized care and a stronger pipeline of genetic therapies. - Gene therapy remains an early-stage catalyst rather than a near-term cure, but the research momentum is enough to influence market expectations.

What's next: - The report expects newborn screening expansion, improved steroid therapies and more personalized treatment approaches to shape the market through 2030. - Continued gene therapy development could further lift long-term expectations if clinical progress continues. - The company also points readers to its expanded 2026 market-report features and contact channels for more information.

The bottom line: - CAH remains a niche but growing market, with treatment innovation and genetic medicine expected to drive the next phase of expansion.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Asia News Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Asia News Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.